Monopar Therapeutics Inc.
MNPRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 11, 2026 | Barclays | $145.00(+32%) | $109.96 | TheFly | |
| Aug 17, 2026 | Morgan Stanley | Maxwell Skor | $130.00(+12%) | $116.18 | TheFly |
| Aug 13, 2026 | Barclays | $128.00(+11%) | $114.90 | TheFly | |
| Aug 13, 2026 | Cantor Fitzgerald | Kristen Kluska | $119.00(+4%) | $114.90 | TheFly |
| Aug 12, 2026 | BTIG | Jeet Mukherjee | $133.00(+16%) | $114.90 | TheFly |
| Jul 23, 2026 | UBS | $125.00(+11%) | $112.48 | StreetInsider | |
| Jul 22, 2026 | H.C. Wainwright | $125.00(+11%) | $112.63 | TheFly | |
| Jun 30, 2026 | BTIG | $117.00(+24%) | $94.56 | StreetInsider | |
| Jun 29, 2026 | UBS | $105.00(+20%) | $87.68 | StreetInsider | |
| Jun 2, 2026 | Piper Sandler | $105.00(+63%) | $64.40 | StreetInsider | |
| Jan 9, 2026 | Morgan Stanley | Maxwell Skor | $115.00(+81%) | $63.40 | TheFly |
| Nov 14, 2025 | Raymond James | Chris Raymond | $123.00(+41%) | $87.01 | StreetInsider |
| Oct 13, 2025 | Barclays | Etzer Darout | $125.00(+42%) | $87.82 | TheFly |
| Oct 6, 2025 | Raymond James | $142.00(+43%) | $99.39 | TheFly | |
| Oct 2, 2025 | Oppenheimer | $115.00(+36%) | $84.73 | TheFly | |
| Sep 29, 2025 | H.C. Wainwright | $105.00(+37%) | $76.63 | TheFly | |
| Sep 25, 2025 | Chardan Capital | Keay Nakae | $85.00(+17%) | $72.69 | TheFly |
| Sep 25, 2025 | Piper Sandler | Biren Amin | $95.00(+31%) | $72.69 | TheFly |
| Sep 24, 2025 | BTIG | $104.00(+42%) | $73.04 | TheFly | |
| Sep 9, 2025 | BTIG | Jeet Mukherjee | $87.00(+94%) | $44.93 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Barclays | maintain | Overweight | Sep 11, 2026 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | Aug 13, 2026 |
| Barclays | maintain | Overweight | Aug 13, 2026 |
| BTIG | maintain | Buy | Aug 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 22, 2026 |
| BTIG | maintain | Buy | Jun 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 29, 2026 |
| Chardan Capital | maintain | Buy | Mar 30, 2026 |
| BTIG | maintain | Buy | Feb 23, 2026 |
| BTIG | maintain | Buy | Feb 2, 2026 |
| Chardan Capital | maintain | Buy | Jan 29, 2026 |
| BTIG | maintain | Buy | Jan 14, 2026 |
| Raymond James | downgrade | Strong Buy →Outperform | Nov 14, 2025 |
| Chardan Capital | maintain | Buy | Nov 13, 2025 |
| Chardan Capital | maintain | Buy | Nov 9, 2025 |
| Raymond James | maintain | Strong Buy | Oct 6, 2025 |
| Oppenheimer | maintain | Outperform | Oct 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 29, 2025 |
| Piper Sandler | maintain | Overweight | Sep 25, 2025 |
| BTIG | maintain | Buy | Sep 25, 2025 |
| Chardan Capital | maintain | Buy | Sep 25, 2025 |
| Chardan Capital | maintain | Buy | Sep 16, 2025 |
| BTIG | maintain | Buy | Sep 15, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Aug 27, 2025 |
| Chardan Capital | maintain | Buy | Aug 13, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.82| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.62 | $-0.64 | — | — |
| May 14, 2026 | $-0.46 | $-1.06 | — | — |
| Mar 27, 2026 | $-0.61 | $-0.51 | — | — |
| Nov 13, 2025 | $-0.48 | $-0.46 | — | — |
| Aug 12, 2025 | $-0.35 | $-0.47 | — | — |
| May 13, 2025 | $-0.38 | $-0.65 | — | — |
| Mar 31, 2025 | $-2.23 | $-0.36 | — | — |
| Nov 8, 2024 | $-0.37 | $-0.46 | — | — |
News
WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company's investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking pl…
Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Profitability This table compares Regenicin and Monopar Therapeutics' net
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate…
Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming months is a major catalyst, with potential FDA approval and Priority Review Voucher upside. ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo and notable neurological improvement versus standard of care.
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.